Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200
Shasha Qi, Lu Deng, Shan Luo, Yuhong Yao, Tao Chen · 2026
Read Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200 by Shasha Qi, Lu Deng, Shan Luo, Yuhong Yao, Tao Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13613202.txt.
Description
Eat-me signals that invite macrophages to devour lymphoma cells are graded by evidence strength in a 2026 review by Shasha Qi and co-authors. The cancer, a fast-growing B-cell lymphoma, already faces many antibody and cell therapies. Five checkpoint axes are scored across protein proof, lab devouring tests, animal data, clinical results, and marker value.
The CD47 axis leads, with the broadest support at every level. Two other axes show real lab promise but thin clinical proof. Two more remain candidates, one backed by deep cell biology rather than lymphoma trials. The maturity ladder helps funders and trial teams back the checkpoints likeliest to pay off.
Catalog record
| CREATOR | Shasha Qi, Lu Deng, Shan Luo, Yuhong Yao, Tao Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |